Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 41 EP688 | DOI: 10.1530/endoabs.41.EP688

1Diskapi Teaching and Research Hospital, Ankara, Turkey; 2Ankara Teaching and Research Hospital, Ankara, Turkey; 3Kastamonu University School of Medicine, Kastamonu, Turkey.

İntroduction: Polycystic ovary syndrome (PCOS) is associated with risk of cardiovascular disease (CVD). Endocan is potential immunoinflammatory and endothelial dysfunction marker that may be linked to CVD. This study aimed to evaluate the risk of CVD in PCOS patients and to identify the novel biomarker for CVD risk.

Material and methods: We analyzed 52 premenopausal women with PCOS and 59 healthy controls. Clinical, biochemical parameters and endocan were analysed.

Result: Ferriman Gallwey score, BMI, waist-hip ratio, HOMA-IR, total testosteron were significantly higher in PCOS than controls. Serum endocan levels were significantly higher in the PCOS compared with the controls (457.19±239.32 vs 356.85±183.48 ng/ml, P=0.015, respectively) (Table 1).

Table 1 The clinical, biochemical analyses of PCOS and controls.
Controls PCOSP
Age (years)25.93±5.2223.46±5.310.015
BMI (kg/m2)22.56±3.2326.90±5.690.001
Waist-hip ratio0.77±0.660.85±0.540.012
Ferriman Gallwey Score6.89±0.9715.11±5.600.001
Glucose (mg/dl)78.44±8.5781.37±7.710.652
Total testosteron (pg/ml)29.96±9.2666.45±27.260.001
Endocan (ng/ml) 356.85±183.48457.19±239.32 0.015

Conclusion: Endocan is a potential inflammatory and CVD biomarker in PCOS. Further studies are needed to assess the relevance of endocan in CVD risk of PCOS.

Article tools

My recent searches

No recent searches.